drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous TCR-T)
drug_description
Autologous, gene-modified TCR-engineered T cells (TCR-T; T-Plex) expressing a high-affinity TCR specific for MAGE-A1 peptide presented by HLA-A*02:01; administered after lymphodepletion to recognize peptide–HLA on tumor cells and induce TCR/CD3-mediated cytotoxic killing.
nci_thesaurus_concept_id
C201067
nci_thesaurus_preferred_term
Autologous Anti-MAGE-A1 TCR-engineered T-cells TSC-204-A0201
nci_thesaurus_definition
A preparation of autologous T-lymphocytes that are engineered to express a T-cell receptor (TCR) specific for melanoma-associated antigen A1 (MAGE-A1) presented on human leukocyte antigen (HLA)-A*02:01, with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-MAGE-A1 TCR-engineered T-cells TSC-204-A0201 specifically recognize and bind to MAGE-A1 expressed on tumor cells. This may lead to cytotoxic T-lymphocyte (CTL)-mediated elimination of tumor cells expressing MAGE-A1. MAGE-A1 is a tumor-associated antigen (TAA) overexpressed by a variety of cancer cell types.
drug_mesh_term
T-Lymphocytes, Transgenic
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified to express a high-affinity TCR specific for the MAGE-A1 peptide presented by HLA-A*02:01. Upon encountering MAGE-A1 peptide–HLA complexes on tumor cells, the engineered T cells engage TCR/CD3 signaling, activate cytotoxic effector functions, and mediate targeted killing of MAGE-A1–expressing cancer cells after lymphodepletion.
drug_name
TSC-204-A0201
nct_id_drug_ref
NCT05973487